Research progress of anti-gout small molecules targeting the NLRP3 inflammasome
10.16438/j.0513-4870.2023-0838
- VernacularTitle:靶向NLRP3炎症小体的抗痛风小分子化合物研究进展
- Author:
Zhen-qian WANG
;
Zhi-jiao ZHANG
;
Xin-yong LIU
;
Peng ZHAN
- Publication Type:Research Article
- Keywords:
NOD-like receptor thermal protein domain associated protein 3;
inflammasome;
gout;
monosodium urate;
small molecule;
bioactivity evaluation
- From:
Acta Pharmaceutica Sinica
2024;59(3):543-553
- CountryChina
- Language:Chinese
-
Abstract:
Currently, clinically used drugs for the treatment of gout inflammation, such as colchicine, nonsteroidal anti-inflammatory drugs, and glucocorticoids, can only relieve the pain of joint inflammation and have severe hepatorenal toxicity and multiple organ adverse reactions. The NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome is a key complex that induces the onset of gout inflammation and has become a crucial target in the development of anti-gout drugs. This article reviews the research progress of anti-gout small molecules targeting the NLRP3 inflammasome and their bioactivity evaluation methods in the past five years, in order to provide information for the development of specific drugs for the treatment of gout inflammation.
